Board of Directors of Artgen Biotech has assessed the company's current financial performance and plans for 2024 and sees no need for an additional share issue, Artgen Biotech CEO Sergey Masyuk said. In 2024, the company will continue to work on expanding the markets and geography of presence of the group's services, Neovasculgen and Histograft products. Work will also continue on bringing to the market the development of advanced stages and obtaining RIs: for vaccines Betuvax-Cov-2, Tetraflubet, Combi 5V.